US Patent Issued to Wyvern Pharmaceuticals on March 3 for "Composition for regulating production of interfering ribonucleic acid" (Canadian Inventor)

ALEXANDRIA, Va., March 3 -- United States Patent no. 12,565,655, issued on March 3, was assigned to Wyvern Pharmaceuticals Inc. (Calgary, Canada).

"Composition for regulating production of interfering ribonucleic acid" was invented by Bradley G. Thompson (Calgary, Canada).

According to the abstract* released by the U.S. Patent & Trademark Office: "The embodiments of the present disclosure relate to decreasing the bioavailability of Fms-like tyrosine kinase 3 (FLT3) by providing a composition that comprises a recombinant plasmid with one or more sequences of miRNA. When the recombinant plasmid interacts with a target cell, it causes the target cell to upregulate production of the miRNA, which then decreases the bioavailability of FLT3."

T...